Theravance Biopharma Inc (FRA:0TB) Stock Price, Trades & News

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	9.74
Equity-to-Asset	0.62
Debt-to-Equity	0.14
Debt-to-EBITDA	0.29
Interest Coverage	2.74
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.5	Distress Grey Safe
Beneish M-Score	-5.13	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

3/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	44
	3-Year Book Growth Rate	-5
	Future 3-5Y Total Revenue Growth Rate Estimate	-6.09

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	44.95
	9-Day RSI	47.43
	14-Day RSI	50.59
	3-1 Month Momentum %	7.75
	6-1 Month Momentum %	-2.55
	12-1 Month Momentum %	61.9

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	13.14
	Quick Ratio	13.14
	Cash Ratio	12.42
	Days Sales Outstanding	77.58

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	7.8
	Shareholder Yield %	1.47

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Operating Margin %	4.54
	Net Margin %	104.34
	EBITDA Margin %	128.74
	FCF Margin %	247.3
	OCF Margin %	247.3
	ROE %	47.3
	ROA %	26.72
	ROIC %	3.76
	3-Year ROIIC %	-64.64
	ROC (Joel Greenblatt) %	373.35
	ROCE %	35.58
	Years of Profitability over Past 10-Year	2
	Moat Score	4
	Tariff Resilience Score	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	7.66
	Forward PE Ratio	6.51
	PE Ratio without NRI	15.84
	Price-to-Owner-Earnings	3.49
	PS Ratio	7.99
	PB Ratio	2.99
	Price-to-Tangible-Book	2.99
	Price-to-Free-Cash-Flow	3.18
	Price-to-Operating-Cash-Flow	3.18
	EV-to-EBIT	3.74
	EV-to-EBITDA	3.67
	EV-to-Revenue	4.73
	EV-to-Forward-Revenue	2.82
	EV-to-FCF	1.93
	Price-to-GF-Value	0.9
	Price-to-Median-PS-Value	0.54
	Price-to-Graham-Number	1.45
	Price-to-Net-Current-Asset-Value	3.68
	Price-to-Net-Cash	4.08
	Earnings Yield (Greenblatt) %	26.74
	FCF Yield %	30.78

Financials (Next Earnings Date:2026-08-12 Est.)

Annual Quarterly TTM

FRA:0TB's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Theravance Biopharma Inc Executives

Details

GF Value™: €16.18

FRA:0TB

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Medium warning signs with 0TB. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	94.243
	EPS (TTM) (€)	1.892
	Beta	0.844
	3-Year Sharpe Ratio	0.51
	3-Year Sortino Ratio	0.99
	Volatility %	48.13
	14-Day RSI	50.59
	14-Day ATR (€)	0.090131
	20-Day SMA (€)	14.665
	12-1 Month Momentum %	61.9
	52-Week Range (€)	9.35 - 17.5
	Shares Outstanding (Mil)	51.83

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Theravance Biopharma Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Theravance Biopharma Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-10 17:00	In 104 days
Third quarter earnings results for 2026	2026-11-10	In 103 days
Second quarter earnings conference call for 2026	2026-08-12 17:00	In 14 days
Second quarter earnings results for 2026	2026-08-12	In 13 days
General meeting for 2026	2026-06-12	14.00 (+0.00%)
First quarter earnings results for 2026	2026-05-07	14.20 (+0.00%)
Annual report for 2025	2026-03-23	12.10 (+0.00%)
Fourth quarter earnings results for 2025	2026-03-19 08:30	12.00 (+0.00%)
8th Annual Evercore Healthcare Conference	2025-12-04 08:20	15.70 (+0.00%)
Third quarter earnings conference call for 2025	2025-11-10 17:00	12.80 (+0.00%)

Show

Entries

Theravance Biopharma Inc Frequently Asked Questions

What is Theravance Biopharma Inc(FRA:0TB)'s stock price today?

The current price of FRA:0TB is €14.60. The 52 week high of FRA:0TB is €17.50 and 52 week low is €9.35.

When is next earnings date of Theravance Biopharma Inc(FRA:0TB)?

The next earnings date of Theravance Biopharma Inc(FRA:0TB) is 2026-08-12 Est..

Does Theravance Biopharma Inc(FRA:0TB) pay dividends? If so, how much?

Theravance Biopharma Inc(FRA:0TB) does not pay dividend.

Press Release

	Subject	Date
	Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders?	2026-07-09
	$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK	2026-07-09
	$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)	2026-06-29
	TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders	2026-06-29
	Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders	2026-06-29
	THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT	2026-06-29
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH	2026-04-30
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH	2026-04-16
	TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates	2026-04-15
	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH	2026-04-09

10/Page

Articles on Theravance Biopharma Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.